Bionomics Limited (BNOX)
After hours:
| Previous Close | 0.2700 |
| Open | 0.2790 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.2751 - 0.3149 |
| 52 Week Range | 0.2310 - 3.8600 |
| Volume | |
| Avg. Volume | 644,531 |
| Market Cap | 5.198M |
| Beta (5Y Monthly) | -0.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.8000 |
| Earnings Date | Sep 30, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
GlobeNewswireBionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
ADELAIDE, Australia and CAMBRIDGE, Mass., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that the Company has been invited to present at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, starting Tuesd
TipRanksBionomics CEO believes company has ‘significant, unrealized value’
Bionomics announced that Spyridon “Spyros” Papapetropoulos M.D., Ph.D., President and Chief Executive Officer of Bionomics, issued a letter to Bionomics shareholders, which read in part, “This year continues to be a pivotal year for Bionomics, characterized by numerous wins and essential changes that have enhanced the Company and furthered our goal of creating therapies for the countless individuals suffering from anxiety and stress disorders…Additionally, we are in the final stages of redomicil
